News|Videos|November 18, 2026

IDSA 2026 AMR Guidance Puts Resistance Mechanisms at Center of Therapy

Ryan Shields, PharmD, MS, explains how rapid diagnostics, aggressive β-lactam dosing in CRRT, and cefepime-zidebactam fit within the IDSA 2026 guidance on antimicrobial-resistant Gram-negative infections.

The Infectious Diseases Society of America (IDSA) 2026 guidance on the treatment of antimicrobial-resistant Gram-negative infections, published on July 30, revised every question from the 2024 version.¹ ² In a recent interview, Ryan Shields, PharmD, MS, associate professor of Medicine, co-director, Antibiotic Management Program, the University of Pittsburgh, said early identification of the resistance mechanism allows clinicians to tailor therapy with the newest β-lactam agents.

The guidance covers ESBL-producing Enterobacterales, AmpC-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa with difficult-to-treat resistance (DTR P aeruginosa), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia.¹ Notable additions include aztreonam-avibactam for NDM-producing CRE and cefiderocol monotherapy as the preferred option for invasive S maltophilia infections.¹ IDSA plans to update the guidance every 1 to 2 years.²

Shields described the guidance’s greatest value as its design as a living document, which lets the panel fold in new antibiotics, real-world evidence, and updated pharmacokinetic and pharmacodynamic data as they emerge.

For Enterobacterales, Shields said rapid molecular tests detecting β-lactamase enzymes offer a predictable view of susceptibility. Common targets include CTX-M, the most frequent ESBL enzyme in the United States, along with the carbapenemases KPC and OXA-48. Detection prompts immediate action, whether targeted definitive therapy or a more informed empiric regimen for patients with prior resistant isolates.

The guidance reflects this mechanism-first approach, adding a new question on how carbapenemase identification should guide treatment of DTR P aeruginosa.¹ It also cites data favoring ceftolozane-tazobactam (Zerbaxa; Merck) over ceftazidime-avibactam (Avycaz; AbbVie), particularly for pneumonia.¹

Shields noted a single enzyme result is far less informative for P aeruginosa, which typically combines β-lactamases with efflux pumps and outer membrane porin changes. In these cases, clinicians must rely on phenotypic antimicrobial susceptibility testing. At his institution, ceftolozane-tazobactam and ceftazidime-avibactam now appear on automated susceptibility panels, eliminating the delay of reflex testing.

Dosing Aztreonam-Avibactam and Cefiderocol for NDM-Producing Enterobacterales With Unstable Renal Function

The 2026 guidance adds aztreonam-avibactam (Emblaveo; AbbVie) for NDM-producing CRE, with a slight preference for it over ceftazidime-avibactam plus aztreonam.¹ It also adds preclinical and clinical comparisons of aztreonam-avibactam with cefiderocol (Fetroja; Shionogi) for NDM-producing infections.¹ Both agents undergo renal elimination and require dose adjustment.

Shields said patients on continuous renal replacement therapy (CRRT) represent the most precarious scenario, because circuit flow rates dictate drug clearance. New data on aztreonam-avibactam dosing by CRRT flow rate were presented at IDWeek 2026, and the cefiderocol product label provides dosing by effluent rate. He advised clinicians to weigh the severity of critical illness and dose β-lactams aggressively.

“Because beta-lactams are so safe, we tend to always kind of round up if we’re between two doses or very aggressive and can later peel off if renal function stabilizes,” said Shields.

Where Cefepime-Zidebactam May Fit Against Metallo-β-Lactamase Producers

The FDA approved cefepime-zidebactam (Zaynich; Wockhardt) on June 1, for adults with complicated urinary tract infections, including pyelonephritis.³ In the phase 3 ENHANCE-1 trial, it achieved a composite clinical cure and microbiologic response rate of 89.0% vs 68.4% with meropenem at test of cure.³ Zidebactam inhibits Ambler class A and C β-lactamases and binds penicillin-binding protein 2 (PBP2), complementing the PBP3 binding of cefepime.³

Shields described this as an enhancer effect, supported by strong in vitro and animal model data against CRE, Acinetobacter, and P aeruginosa. He identified two possible initial roles: NDM-producing Escherichia coli resistant to aztreonam-avibactam or cefiderocol, and metallo-β-lactamase–producing P aeruginosa, such as VIM producers. The agent was not yet available on the US market at the time of the interview, and Shields said real-world studies will clarify its place.

“The guidance really gives us a compendium to continue to add and push the envelope. Because in infectious diseases, particularly in antimicrobial resistance, we’re learning so rapidly,” said Shields.

Shields also pointed to new oral agents, including gepotidacin, pivmecillinam, and sulopenem, now incorporated into the guidance for ESBL- and AmpC-producing Enterobacterales.¹ He said formulary decisions among these options should start with local, regional, and hospital-level epidemiology.

References
  1. Infectious Diseases Society of America. IDSA 2026 guidance on the treatment of antimicrobial-resistant gram-negative infections. Published July 30, 2026. Accessed November 18, 2026. https://www.idsociety.org/practice-guideline/amr-guidance/
  2. IDSA updates guidance on resistant gram-negative infections. Healio. Published August 26, 2026. Accessed November 18, 2026. https://www.healio.com/news/infectious-disease/20260826/idsa-updates-guidance-on-resistant-gramnegative-infections
  3. FDA approves cefepime and zidebactam for complicated UTI. Urology Times. Published June 1, 2026. Accessed November 18, 2026. https://www.urologytimes.com/view/fda-approves-cefepime-and-zidebactam-for-complicated-uti

Related to this article

FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.